Mirapexin

pramipexole

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Mirapexin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mirapexin.

What is Mirapexin?

Mirapexin is a medicine that contains the active substance pramipexole. It is available as ‘immediate-release’ white tablets (round: 0.088, 0.7 and 1.1 mg; oval: 0.18 and 0.35 mg) and as ‘prolonged-release’ white tablets (round: 0.26 and 0.52 mg; oval: 1.05, 1.57, 2.1, 2.62 and 3.15 mg). Immediate-release tablets release the active substance immediately, and prolonged-release tablets release it slowly over a few hours.

What is Mirapexin used for?

Mirapexin is used to treat the symptoms of the following diseases:

  • Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Mirapexin can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective;
  • moderate to severe restless-legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night. Mirapexin is used when a specific cause for the disorder cannot be identified.

The medicine can only be obtained with a prescription.

How is Mirapexin used?

For Parkinson’s disease, the starting dose is either one 0.088-mg immediate-release tablet three times a day or one 0.26-mg prolonged-release tablet once a day. The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated. The maximum daily dose is three 1.1-mg immediate-release tablets or one 3.15-mg prolonged-release tablet. Patients can be switched from the immediate- to the prolonged-release tablets overnight, but the dose might need to be adjusted depending on the patient’s response. Mirapexin must be given less often in patients who have problems with their kidneys. If treatment is stopped for any reason, the dose should be decreased gradually.

For restless-legs syndrome, Mirapexin immediate-release tablets should be taken once a day, two to three hours before going to bed. The recommended starting dose is 0.088 mg, but, if needed, this can be increased every four to seven days to reduce symptoms further, to a maximum of 0.54 mg. The patient’s response and the need for further treatment should be evaluated after three months. The prolonged-release tablets are not suitable for restless-legs syndrome.

Mirapexin tablets should be swallowed with water. The prolonged-release tablets must not be chewed, divided or crushed, and should be taken around the same time every day. For more information, see the package leaflet.

How does Mirapexin work?

The active substance in Mirapexin, pramipexole, is a dopamine agonist (a substance that imitates the action of dopamine). Dopamine is a messenger substance in the parts of the brain that control movement and coordination. In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.

The way pramipexole works in restless legs syndrome is not fully understood. The syndrome is thought to be caused by problems in the way dopamine works in the brain, which may be corrected by pramipexole.

How has Mirapexin been studied?

In Parkinson’s disease, Mirapexin immediate-release tablets have been studied in five main studies. Four studies compared Mirapexin with placebo (a dummy treatment): one study in 360 patients with advanced disease who were already taking levodopa that was starting to become less effective, and three studies in a total of 886 patients with early disease who were not receiving levodopa. The main measure of effectiveness was the change in the severity of Parkinson’s disease. The fifth study compared Mirapexin with levodopa in 300 patients with early disease, and measured the number of patients who had movement symptoms.

To support the use of the prolonged-release tablets, the company presented the results of studies showing that the immediate- and prolonged-release tablets produced the same levels of the active substance in the body. It also presented studies comparing the two tablets in early and advanced Parkinson’s disease, and looking at switching patients from immediate- to prolonged-release tablets. In restless-legs syndrome, Mirapexin immediate-release tablets have been studied in two main studies.

The first compared Mirapexin with placebo over 12 weeks in 344 patients and measured the improvement in symptoms. The second included 150 patients who took Mirapexin for six months, and compared the effects of remaining on Mirapexin with switching to placebo. The main measure of effectiveness was the time until symptoms got worse.

What benefit has Mirapexin shown during the studies?

In the study of patients with advanced Parkinson’s disease, patients taking Mirapexin immediate-release tablets had larger improvements after 24 weeks of steady-dose treatment than those taking placebo. Similar results were seen in the first three studies of early Parkinson’s disease, with greater improvements after four or 24 weeks. Mirapexin was also more effective than levodopa at improving movement symptoms in early disease.

The additional studies showed that the prolonged-release tablets were as effective as the immediate-release tablets in treating Parkinson’s disease. They also showed that patients can be safely switched from immediate- to prolonged-release tablets, although dose adjustments were needed in a small number of patients.

In restless-legs syndrome, Mirapexin immediate-release tablets were more effective than placebo at reducing symptoms over 12 weeks, but the difference between placebo and Mirapexin was greatest after four weeks before getting smaller. The results of the second study were insufficient to prove the long-term effectiveness of Mirapexin.

What is the risk associated with Mirapexin?

The most common side effect with Mirapexin (seen in more than 1 patient in 10) is nausea (feeling sick). In patients with Parkinson’s disease, the following side effects are also seen in more than 1 patient in 10: dizziness, dyskinesia (difficulty controlling movement) and somnolence (sleepiness). For the full list of all side effects reported with Mirapexin, see the package leaflet.

Mirapexin should not be used in people who may be hypersensitive (allergic) to pramipexole or any of the other ingredients.

Why has Mirapexin been approved?

The CHMP decided that Mirapexin’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Mirapexin

The European Commission granted a marketing authorisation valid throughout the European Union for Mirapexin on 23 February 1998. The marketing-authorisation holder is Boehringer Ingelheim International GmbH. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Mirapexin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Mirapexin : EPAR - Summary for the public BG = bălgarski 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public ES = español 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public CS = čeština 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public DA = dansk 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public DE = Deutsch 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public ET = eesti keel 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public EL = elliniká 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public EN = English 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public FR = français 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public IT = italiano 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public LV = latviešu valoda 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public LT = lietuvių kalba 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public HU = magyar 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public MT = Malti 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public NL = Nederlands 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public PL = polski 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public PT = português 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public RO = română 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public SK = slovenčina 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public SL = slovenščina 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public FI = suomi 2009-11-17 2011-01-05
Mirapexin : EPAR - Summary for the public SV = svenska 2009-11-17 2011-01-05

This EPAR was last updated on 11/07/2018 .

Authorisation details

Product details

Product details for Mirapexin
NameMirapexin
Agency product numberEMEA/H/C/000134
Active substance

pramipexole dihydrochloride monohydrate

International non-proprietary name (INN) or common name

pramipexole

Therapeutic area Restless Legs SyndromeParkinson Disease
Anatomical therapeutic chemical (ATC) code N04BC05

Publication details

Publication details for Mirapexin
Marketing-authorisation holder

Boehringer Ingelheim International GmbH

Revision32
Date of issue of marketing authorisation valid throughout the European Union23/02/1998

Contact address:

Boehringer Ingelheim International GmbH
D-55216 Ingelheim am Rhein
Germany

Product information

Product information

20/06/2018  Mirapexin -EMEA/H/C/000134 -N/0087

Name Language First published Last updated
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11
Mirapexin : EPAR - Product Information SV = svenska 2009-11-17 2018-07-11

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12
Mirapexin : EPAR - All Authorised presentations SV = svenska 2009-11-17 2010-07-12

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).

Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

Assessment History

Authorised

This medicine is approved for use in the European Union

More information on Mirapexin